Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
Details : AV-GBM-1 is a novel immunotherapy consisting of autologous dendritic cells loaded with autologous tumor neoantigens derived from self-renewing tumor-initiating cells isolated from tumors after routine surgical debulking.
Product Name : AV-GBM-1
Product Type : Vaccine
Upfront Cash : Inapplicable
August 06, 2021
Lead Product(s) : AV-COVID-19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : PT AIVITA Biomedika
Deal Size : Inapplicable
Deal Type : Inapplicable
AIVITA Biomedical Completes Phase 1 Study of Personalized COVID-19 Vaccine Candidate, AV-COVID-19
Details : AV-COVID-19 is being manufactured locally by AIVITA. AIVITA is in discussions with regulatory authorities for a Phase 2 study in Indonesia, as well as clinical investigation of AV-COVID-19 in the United States in early 2021.
Product Name : AV-COVID-19
Product Type : Vaccine
Upfront Cash : Inapplicable
February 25, 2021
Lead Product(s) : AV-COVID-19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : PT AIVITA Biomedika
Deal Size : Inapplicable
Deal Type : Inapplicable
AIVITA Biomedical Closes $25 Million Financing Round
Details : Proceeds will support clinical development of AIVITA’s personalized immunotherapy programs, including Phase 2 studies in glioblastoma and ovarian cancer, as well as AIVITA’s application for commercial approval of its melanoma immunotherapy.
Product Name : AV-GBM-1
Product Type : Vaccine
Upfront Cash : Undisclosed
December 29, 2020
AIVITA Biomedical's Phase 2 Glioblastoma Trial Shows Improved Progression Free Survival
Details : The analysis focused on 57 patients who were scheduled to receive up to eight doses of AV-GBM-1 over approximately six months. At the time of the analysis, surviving patients had completed therapy and had been followed between 7.2 and 24.2 months.
Product Name : AV-GBM-1
Product Type : Vaccine
Upfront Cash : Inapplicable
November 17, 2020
Details : AIVITA provided update of its Phase 2 trial of AV-GBM-1 in newly diagnosed glioblastoma and Phase 2 trial of AVOVA-1 in advanced ovarian cancer. Both the studies showed encouraging data.
Product Name : AV-GBM-1
Product Type : Vaccine
Upfront Cash : Inapplicable
April 27, 2020
AIVITA Biomedical Completes Patient Recruitment in Phase 2 GBM Trial
Details : The trial has achieved its enrollment target ahead of schedule and under budget, with a notable 94% treatment manufacturing success rate.
Product Name : AV-GBM-1
Product Type : Vaccine
Upfront Cash : Inapplicable
April 02, 2020
Details : Randomized trials have failed to confirm significant anticancer activity for monotherapy GM-CSF, but it appears to provide immune enhancing effects and survival benefit when it is admixed with dendritic cells loaded ex-vivo with autologous tumor antigens
Product Name : AVOVA-1
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 08, 2020
Details : The eight-site, single-arm study investigates AV-GBM-1, AIVITA’s novel immunotherapy for the treatment of glioblastoma that targets the autologous tumor-initiating cells responsible for the rapid growth and proliferation of the disease.
Product Name : AV-GBM-1
Product Type : Vaccine
Upfront Cash : Inapplicable
February 11, 2020
Reset All
